The current disclosure provides systems and methods for monitoring a whole-body fatigue (WBF) of a worker while the worker performs physical activity (e.g., labor) via a wearable WBF assessment device worn by the worker. The WBF is calculated using a critical power (CP) bioenergetic model that is individually calibrated to the worker based on periodic WBF self-assessments performed by the worker via the WBF assessment device. The WBF assessment device includes a biosensor that monitors the worker's heart rate. The customized CP model is based on estimating a physical intensity of the physical activity based on a percentage of heart rate reserve (% HRR) of the worker calculated from the heart rate.
A61B 5/024 - Mesure du pouls ou des pulsations cardiaques
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/16 - Dispositifs pour la psychotechnieTest des temps de réaction
G09B 23/28 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la médecine
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
2.
METHODS OF ADJUSTING CARBON AND SILICA CONTENT IN RICE HULL ASH (RHA) BYPRODUCTS TO CONTROL CARBOTHERMAL REDUCTION FORMING NANOSTRUCTURED SILICON CARBIDE, SILICON NITRIDE, SILICON OXYNITRIDE NANOCOMPOSITES
In various aspects, methods of making a silicon carbide or silicon nitride from rice hull ash (RHA) byproduct are provided. A treated silica depleted rice hull ash product (SDRHA) comprising silicon oxide at ≤about 65% by weight and carbon ≥about 35% by weight may be heated in an environment free of any additional carbon sources, but in an inert atmosphere, having a temperature of ≥about 1,200° C. to ≤about 1,700° C. for a carbothermal reaction that forms a product (e.g., nanocomposite product) comprising at least one of silicon carbide (SiC), silicon nitride (Si3N4), and silicon oxynitride (Si2N2O or non-stoichiometric SiNxO4-x, where x ranges from greater than 0 to less than 4). A negative electroactive material is also provided that includes silicon oxynitride (Si2N2O), which may be used in a lithium ion battery.
H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p. ex. LiTi2O4 ou LiTi2OxFy
A method for generating personalized responses in a conversation with a user includes generating real-time contexts capturing an environment of the user over time, including generating a particular real-time context based on a first data stream corresponding to a first modality in an environment of the user and a second data stream corresponding to a second modality in the environment of the user, generating historical contexts based on the real-time contexts, in response to receiving a conversational cue provided by the user, generating a current real-time context based on data corresponding to the first modality and the second modality in a current environment of the user, and generating, based on the current real-time context, a personalized response to the conversational cue, including identifying, based on the current real-time context, relevant user information, including identifying one or more relevant historical contexts, and generating the personalized response using the relevant user information.
H04L 51/02 - Messagerie d'utilisateur à utilisateur dans des réseaux à commutation de paquets, transmise selon des protocoles de stockage et de retransmission ou en temps réel, p. ex. courriel en utilisant des réactions automatiques ou la délégation par l’utilisateur, p. ex. des réponses automatiques ou des messages générés par un agent conversationnel
G06V 40/16 - Visages humains, p. ex. parties du visage, croquis ou expressions
G06V 40/18 - Caractéristiques de l’œil, p. ex. de l’iris
G10L 15/26 - Systèmes de synthèse de texte à partir de la parole
G10L 25/63 - Techniques d'analyse de la parole ou de la voix qui ne se limitent pas à un seul des groupes spécialement adaptées pour un usage particulier pour comparaison ou différentiation pour estimer un état émotionnel
4.
THERMALLY ACTIVATED DELAYED FLUORESCENCE (TADF) MATERIALS FOR HIGH EFFICIENCY ORGANIC PHOTOVOLTAICS
Described are organic photovoltaic devices comprising an anode; a cathode; and a photoactive organic material in a layer disposed between the anode and the cathode, the energy difference between the triplet energy state (T1) and the singlet energy state (S1) (ΔEST) in the photoactive organic material is less than about 300 meV; and when the organic photovoltaic device is illuminated with light having an AM1.5 spectrum, the organic photovoltaic device has an open circuit voltage of greater than 0.9 V, a power conversion efficiency of greater than 22%, and an EL external quantum efficiency >5%.
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
H10K 30/20 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant des jonctions organiques-organiques, p. ex. des jonctions donneur-accepteur
H10K 30/57 - Dispositifs photovoltaïques [PV] comprenant des jonctions multiples, p. ex. des cellules PV en tandem
H10K 85/60 - Composés organiques à faible poids moléculaire
An eLSD control system includes: an eLSD configured to adjust torque to shafts of an axle of a vehicle; a preemptive planar coordinator module configured to determine targets for an eLSD clutch torque and generate a first clutch torque request based on the targets; a direct yaw feedback control module configured to track a target yaw rate for the vehicle, determine a yaw rate error, and generates a second clutch torque request to reduce the yaw rate error; a wheel stability control module configured to generate a third clutch torque request to minimize at least one of i) slip between wheels of the axle, and ii) slip on one of the wheels experiencing higher traction; and a core arbitration clutch response module configured to control the eLSD clutch torque of the eLSD based on the first clutch torque request, the second clutch torque request, and the third clutch torque request.
F16H 48/34 - Dispositions pour supprimer ou modifier l'action différentielle, p. ex. dispositifs de verrouillage utilisant des moyens actionnés de l'extérieur utilisant des actionneurs électromagnétiques ou électriques
F16H 48/20 - Dispositions pour supprimer ou modifier l'action différentielle, p. ex. dispositifs de verrouillage
F16H 48/22 - Dispositions pour supprimer ou modifier l'action différentielle, p. ex. dispositifs de verrouillage utilisant des embrayages ou des freins à friction
6.
POSITIONING COMPOSITIONS, SYSTEMS, AND METHODS FOR THE HOMEOSTASIS OF PROTEIN-BASED ORGANELLES
Provided herein are compositions, systems, and methods for the assembly of a positioning system for protein-based organelles within a cell of an organism. In particular, the present invention relates to systems of homeostasis for both synthetic and natural bacterial protein-based organelles including bacterial microcompartments, encapsulin nanocompartments, and biomolecular condensates.
B01D 53/32 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par effets électriques autres que ceux prévus au groupe
8.
SOURCE MATERIAL CONFIGURATION IN ORGANIC DEPOSITION APPARATUS
An organic-infused substrate for use in organic vapor deposition apparatus and processes is disclosed. The organic-infused substrate includes a substrate such as a mesh, and an organic material adhered to the substrate. The organic-infused substrate provides consistent, repeatable, and controllable deposition rates of organic material from the organic-infused substrate onto the deposition substrate. The organic material can include an active pharmaceutical ingredient (API). Related cartridges, nozzles, apparatus, and methods incorporating or using the organic-infused substrate are also disclosed.
B41J 2/01 - Machines à écrire ou mécanismes d'impression sélective caractérisés par le procédé d'impression ou de marquage pour lequel ils sont conçus caractérisés par la mise en contact sélective d'un liquide ou de particules avec un matériau d'impression à jet d'encre
B41J 2/015 - Machines à écrire ou mécanismes d'impression sélective caractérisés par le procédé d'impression ou de marquage pour lequel ils sont conçus caractérisés par la mise en contact sélective d'un liquide ou de particules avec un matériau d'impression à jet d'encre caractérisés par le procédé de formation du jet
A ducted turbine (10) includes a turbine (12) having a plurality of blades (14) extending from a hub (36) that rotate together about a turbine axis (X). The turbine (12) is surrounded by a coaxial duct (16) having an inner surface (22) radially outboard of the turbine. The duct (16) has a diameter (D) that changes along the axial direction such that its inner surface (22) has a curvilinear profile in an axially extending plane. The duct (16) accelerates and conditions fluid flowing past the turbine blades (14) to enhance energy extraction efficiency. The geometry of the duct (16) and the turbine blades (12) can be optimized using computational fluid dynamics (CFD) with a blade-resolved Reynolds-averaged Navier-Stokes (RANS) solver. To handle the high-dimensional design space of the blade and duct geometry, a gradient-based optimization can be performed with gradients computed by the adjoint method. The optimized geometries can provide the ducted turbine (10) with an efficiency significantly higher than that of a typical unducted turbine.
F03B 17/06 - Autres "machines" ou machines motrices utilisant un écoulement de liquide, p. ex. du type à clapets oscillants
G06F 111/06 - Optimisation multi-objectif, p. ex. optimisation de Pareto utilisant le recuit simulé, les algorithmes de colonies de fourmis ou les algorithmes génétiques
The present disclosure relates to bone targeting therapeutic conjugates and uses thereof. In particular, the disclosure relates to bone targeting therapeutic conjugates comprising a therapeutic antibody for treatment of a bone disease and a bone targeting moiety.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
Provided herein are compositions comprising polypeptide carriers to auto-tune polypeptide drug conjugate (e.g., antibody drug conjugate) targeting for increased tissue penetration and efficacy in the treatments for diseases or disorders utilizing polypeptide drug conjugates. The carrier polypeptide has a lower affinity for a target of the polypeptide drug conjugate as compared to the polypeptide drug conjugate and a tunable avidity based on expression condition of the target and high avidity for the target under conditions of high expression of the target.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
Systems and methods for object and material recognition are provided and include a hyperspectral infrared camera that captures a three-dimensional image of an object and black-body emissions data indicating a polarization of black-body radiation emitted from the object. An image processing device accesses a database of expected polarization signatures of black-body emissions from materials at different temperatures and determines a material of the object based on (i) the black-body emissions data indicating the polarization of the black-body radiation emitted from the object, (ii) an ambient temperature of the environment of the system, and (iii) the database of expected polarization signatures of black-body emissions from a plurality of materials for different temperatures.
G01J 4/04 - Polarimètres utilisant des moyens de détection électriques
G01J 5/59 - Pyrométrie des radiations, p. ex. thermométrie infrarouge ou optique en utilisant la polarisationLeurs détails
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
G06V 20/58 - Reconnaissance d’objets en mouvement ou d’obstacles, p. ex. véhicules ou piétonsReconnaissance des objets de la circulation, p. ex. signalisation routière, feux de signalisation ou routes
H04N 23/11 - Caméras ou modules de caméras comprenant des capteurs d'images électroniquesLeur commande pour générer des signaux d'image à partir de différentes longueurs d'onde pour générer des signaux d'image à partir de longueurs d'onde de lumière visible et infrarouge
13.
ELECTROCHEMICAL SYNTHESIS OF DIRECT REDUCED METAL AND METAL-DERIVED COMPOUNDS
An electrowinning process for reduction of metal from a metal-containing ore in an electrochemical cell comprising oppositely disposed electrodes immersed in a water-in-salt electrolyte can include dissolving the metal-containing ore in the water-in-salt electrolyte under acidic conditions to form a solution comprising one or more metal cations from the metal-containing order; and applying a potential to selectively deposit one or more of the metal cations from the solution onto one of the electrodes, thereby growing a high-purity metal plate on the electrode.
C25C 1/06 - Production, récupération ou affinage électrolytique des métaux par électrolyse de solutions des métaux du groupe du fer, de métaux réfractaires ou du manganèse
C25C 5/02 - Production, récupération ou affinage de poudres métalliques ou de métaux poreux à partir de solutions
C22B 3/06 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés par lixiviation dans des solutions inorganiques acides
C22B 5/00 - Procédés généraux de réduction appliqués aux métaux
14.
OXYGENATED HETEROCYCLIC LSD-1 INHIBITORS AND RELATED METHODS OF USE
Disclosed herein is a class of small-molecules having oxygenated heterocyclic ring structure. Compounds disclosed herein are lysine demthylase-1 (LSD-1) inhibitors, and accordingly, also disclosed herein is the use the compounds as therapeutics for the treatment of hematological disorders (e.g., sickle cell disease (SCD), β-thalassemia), cancer (e.g., acute myeloid leukemia (AML), multiple myeloma, biliary tract cancer, non-small cell lung cancer (NSCLC), chronic lymphocytic leukemia, advanced solid tumor, advanced malignancies), and/or a neurological disorder (e.g., Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Parkinson disease (PD), Schizophrenia, Huntington disease (HD)), a metabolic disorder (e.g., type-2 diabetes (T2D), obesity) and other conditions related to LSD-1 activity (e.g., mild to moderate Alzheimer's disease, myocardial fibrosis, autism, complex neurodevelopmental diseases).
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to pharmaceutical combinations comprising a backbone cyclized peptidic CXCR4 inhibitor, a focal adhesion kinase inhibitor (FAKi) and an inhibitor of PD-1 and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.
The present invention relates to pharmaceutical combinations comprising a backbone cyclized peptidic CXCR4 inhibitor and an inhibitor of PD-1 and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.
A device includes a substrate and a heterostructure supported by the substrate. The heterostructure includes a set of quantum dot structures, each quantum dot structure of the set of quantum dot structures including a semiconductor material, and a layered material disposed between the set of quantum dot structures and the substrate. The layered material includes a plurality of monolayers such that adjacent monolayers of the plurality of monolayers are bonded to one another via van der Waals forces, and the semiconductor material of each quantum dot structure of the set of quantum dot structures exhibits bonding via van der Waals forces.
H10F 77/14 - Forme des corps semi-conducteursFormes, dimensions relatives ou dispositions des régions semi-conductrices au sein des corps semi-conducteurs
B82Y 20/00 - Nano-optique, p. ex. optique quantique ou cristaux photoniques
B82Y 40/00 - Fabrication ou traitement des nanostructures
C01B 21/06 - Composés binaires de l'azote avec les métaux, le silicium ou le bore
C01B 21/064 - Composés binaires de l'azote avec les métaux, le silicium ou le bore avec le bore
H10F 71/00 - Fabrication ou traitement des dispositifs couverts par la présente sous-classe
18.
Stochastic Model Predictive Control For Electric Vehicles Thermal Management
A stochastic Model Predictive Control approach is developed to efficiently optimize the thermal management of electric vehicles and accommodate scenarios with multiple routes. To account for the uncertainties, the cost function is constructed to minimize the expected cost across all possible routes over the prediction horizon. Thermal constraints are treated as soft constraints using slack variables. This approach allows for flexibility in satisfying the constraints while optimizing the performance. Through simulations, the performance of the proposed method is evaluated using a fleet of vehicles. In this way, the proposed method achieves a good trade-off between multiple competing performance metrics. Furthermore, an adaptation strategy is introduced, which dynamically adjusts the penalty weight value. This adaptive approach eliminates the need for offline calibration and further enhances performance. The results indicate that the time-varying penalty weight significantly reduces the total constraint violations by up to 20% without impacting the performance on energy consumption.
The Board of Trustees of the University of Illinois (USA)
Inventeur(s)
Sturt, Bradley
Halderman, John Alexander
Crimmins, Braden L.
Abrégé
The following relates generally to error detection in voting systems, and, in particular voting systems using optical scan machines. In some embodiments, one or more processors are configured to: (1) capture, with an optical scan machine, original image data; (2) isolate a first subimage of the original image data; (3) associate the first subimage with a first configuration file candidate, wherein the first configuration file candidate is indicated by a configuration file configuring the optical scan machine, and wherein the association is done according to the configuration file; and (4) display the first subimage along with a representation of the first configuration file candidate.
H04L 9/06 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité l'appareil de chiffrement utilisant des registres à décalage ou des mémoires pour le codage par blocs, p. ex. système DES
H04N 1/107 - Dispositions de balayage employant des supports d'images plans avec un balayage manuel
A gas detector is presented. The gas detector is comprised of: an ionization chamber, an ionization source, a pair of collection electrodes and a p-n junction. The ionization source is configured to ionize molecules of the gas sample residing in the ionization chamber. The pair of collection electrodes are arranged proximate to the ionization chamber and configured to apply a collection voltage across the pair of collection electrodes. The p-n junction is disposed adjacent to a first electrode of the pair of collection electrodes and electrically coupled to the first electrode. During operation, electrons (or negative ions) produced by ionization are collected by the first electrode electrically coupled to the p-n junction and then accelerated in the depletion region by the electric field of the reversely biased p-n junction to form avalanche electrons. Consequently, the signal can be amplified, which in turn increases the sensitivity of the gas detector.
G01N 27/66 - Utilisation de l'onde ou de la radiation des particules pour ioniser un gaz, p. ex. dans une chambre d'ionisation et mesure de l'intensité ou de la tension électriques
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
Noninvasive suture delivery devices are disclosed. In accordance with an implementation, a suture delivery device includes a handle, a first arm, a second arm, and a crimp assembly. The first arm is coupled to and extends from the handle and has a distal end. The distal end of the first arm has a fastener aperture and a first suture holder having an opening and a groove. The second arm extends from the handle and has a distal end. The distal end of the second arm has a second suture holder having an opening and a groove. The fastener aperture is to carry a fastener and actuating the crimp assembly enables the crimp assembly to crimp the fastener.
A61B 17/04 - Instruments, dispositifs ou procédés chirurgicaux pour refermer les plaies ou les maintenir ferméesAccessoires utilisés en liaison avec ces opérations pour la suture des plaiesSupports ou emballages pour aiguilles ou matériaux de suture
A61B 17/42 - Instruments ou procédés de gynécologie ou d'obstétrique
22.
CHROMATOGRAPHIC SEPARATION OF CHIRAL BIOLOGICAL AND MAN-MADE NANOSTRUCTURES ON A CHIRAL STATIONARY PHASE
233), and a plurality of chiral particles, for example, comprising an assembly of nanoribbons that defines a bowtie shape. A chromatography device for separating and/or analyzing chirality of one or more target analytes in a sample by using such a stationary phase in a flow path of a chromatographic device is also provided. Further, methods of separating and/or analyzing chirality of one or more target analytes in a chiral chromatography device incorporating such a chromatographic device are also provided.
Traveling-wave modulation is a form of space-time modulation which has been shown to enable unique electromagnetic phenomena such as non-reciprocity, beam-steering, frequency conversion, and amplification. The capability to accurately simulate spatially-discrete traveling-wave modulated structures is critical to design. However, simulating these structures is challenging due to the complex space-time dependence of the constituent unit cells. Thus, an interpath relation is derived for spatially-discrete traveling-wave modulated structures. The interpath relation reveals that the field within a single time-modulated unit cell (rather than an entire spatial period) is sufficient to determine the field solution throughout space. It is shown that the interpath relation can be incorporated into existing periodic method of moments solvers simply by modifying the source basis functions. As a result, the computational domain is reduced from an entire spatial period to a single time-modulated unit cell, dramatically reducing the number of unknowns.
G02F 1/01 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur
24.
CDK12/13 COVALENT INHIBITORS OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF
Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (Chine)
Inventeur(s)
Chinnaiyan, Arul M.
Wang, George X.
Chang, Yu
Tien, Jean
Ding, Ke
Yang, Jianzhang
Huang, Weixue
Wang, Zhen
Abrégé
The present invention relates to a method for preparing a class of novel CDK12/13 covalent inhibitors or a pharmaceutical composition thereof, and use thereof. The class of novel CDK12/13 covalent inhibitors of the present invention have a structure shown in formula (I). Such compounds can serve as protein kinase inhibitors, can effectively and highly selectively inhibit the CDK12/13 protein kinase activity, and can inhibit the proliferation, migration, and invasion of various tumor cells.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C12P 17/04 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'oxygène comme unique hétéro-atome du cycle contenant un hétérocycle à cinq chaînons, p. ex. griséofulvine
B82Y 99/00 - Matière non prévue dans les autres groupes de la présente sous-classe
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
Inventeur(s)
Oh, Sewoong
Liu, Xiyang
Mahdavifar, Hessam
Jamali, Mohammad Vahid
Viswanath, Pramod
Makkuva, Ashok
Abrégé
In some embodiments, a method of encoding a set of information bits to produce a codeword that encodes the set of information bits for reliable communication is provided. The set of information bits is received. The set of information bits are provided to a plurality of permutation layers separated by neural network processing layers. Each permutation layer accepts an input vector and generates a reordered output vector that is a reordering of the input vector. Each neural network processing layer accepts a vector of input values and generates a vector of output values based on a non-linear function of the vector of input values. The reordered output vector of a final permutation layer of the plurality of permutation layers is provided as the codeword. In some embodiments, a corresponding method of decoding a codeword to retrieve a set of information bits is provided.
H03M 13/21 - Codes non linéaires, p. ex. conversion de mots de données à m bits en mots de code à n bits [mBnB] avec détection ou correction d'erreurs
H03M 13/00 - Codage, décodage ou conversion de code pour détecter ou corriger des erreursHypothèses de base sur la théorie du codageLimites de codageMéthodes d'évaluation de la probabilité d'erreurModèles de canauxSimulation ou test des codes
H03M 13/37 - Méthodes ou techniques de décodage non spécifiques à un type particulier de codage prévu dans les groupes
27.
REAL-TIME PROTECTION FOR MOBILE DEVICES FROM SHOULDER SURFING
People use mobile devices ubiquitously for computing, communication, storage, web browsing, and more. Shoulder surfing occurs when a person near a mobile user peeks at the user's mobile device, potentially acquiring passcodes, PINs, browsing behavior, or other personal information. A technique is presented to protect information on a mobile device from shoulder surfing. The technique is designed to protect all types of on-screen information in real time, without any serious impediment to users' interactions with their mobile devices. In particular, images are generated that appear readable at close distances, but appear blurry or pixelated at farther distances and wider angles. This approach is capable of protecting on-screen information from shoulder surfers, operating in real time, and being minimally intrusive to the intended users.
A method of manufacturing and assembling a sandwich flexure mechanism assembly is set forth herein. The method involves manufacture of a monolithic sandwich flexure module having a multitude of out of plane rigid inter-stage connections between at least some sets of twin stages of the monolithic sandwich flexure module. The method further involves assembling an interconnect subassembly to intermediate bodies of the monolithic sandwich flexure module. The interconnect subassembly furnishing in-plane rigid inter-stage connections between pairs of the intermediate bodies that constitute sister stages of the monolithic sandwich flexure module. The method can further involve assembling a motion body, actuators, and displacement sensors at the monolithic sandwich flexure module.
Methods and systems are herein provided for continuous ultrasound-based assessment of cerebral autoregulation. In one example, a method comprises continuously correlating cerebral blood flow data with systemic blood flow data to generate a flow index indicative of cerebral autoregulation status.
A reconfigurable printing bed device for additive manufacturing or three dimensional (3D) printing includes a reconfigurable printing bed defining a surface configured to receive a deposited material. The bed includes a lattice component comprising a plurality of connected cells each having an open region. The bed includes a flexible elastomeric polymer disposed with the open regions to define a flexible mat. A plurality of actuatable pins is disposed beneath the bed. Each pin is connected to a location on the reconfigurable printing bed to translate it to a predetermined position so that the reconfigurable printing bed is capable of defining a structure having at least a single curvature. Methods of additive manufacturing on such a dynamic reconfigurable printing bed are also contemplated. After passing through a 3D printing extruder, the flowable material may be deposited onto a surface of a reconfigurable printing bed where it hardens as a printed structure.
B29C 70/12 - Façonnage de matières composites, c.-à-d. de matières plastiques comprenant des renforcements, des matières de remplissage ou des parties préformées, p. ex. des inserts comprenant uniquement des renforcements, p. ex. matières plastiques auto-renforçantes des renforcements fibreux uniquement caractérisées par la structure des renforcements fibreux utilisant des fibres courtes, p. ex. sous forme d'un mat
Systems and methods for segmenting one or more lesions from medical image patches are provided. An input medical image patch depicting one or more lesions is received. The one or more lesions are segmented from the input medical image patch using a plurality of machine learning based segmentation networks to respectively generate a plurality of initial segmentation masks. Each of the plurality of machine learning based segmentation networks is trained to segment lesions from patches with a different field of view size. A final segmentation mask of the one or more lesions is generated based on the plurality of initial segmentation masks. The final segmentation mask of the one or more lesions is output.
The present disclosure contemplates an additively manufactured structure for supporting plant growth (e.g., a green wall for supporting diverse plant growth). It includes a wall defining an internal and external surface. The external surface has vessels formed at different locations, wherein each vessel has an opening leading to a storage volume. At least two different vessels have different storage volumes. At least a portion of the wall is additively manufactured and each of the plurality of vessels is configured to receive a growth medium and a portion of a plant. The structure may further include at least one irrigation conduit configured to receive water that is in fluid communication with at least a portion of one of the plurality of vessels. Computational methods for designing a pattern for additively manufacturing a structure for supporting plant growth are also provided.
A method for fabricating an organic electronic device comprises providing a plurality of photoresist structures on a substrate, the substrate having a first electrode layer, the photoresist structures having a bottom surface attached to the substrate and a top surface opposite the bottom surface, the top surface having a dimension greater than a dimension of the bottom surface, positioning a mask over the structures, the mask having a plurality of openings, and depositing an emissive material over the substrate through at least one of the plurality of openings to form at least one emissive element. An organic electronic device and a method of fabricating an organic electronic component are also described.
H10K 71/16 - Dépôt d'une matière active organique en utilisant un dépôt physique en phase vapeur [PVD], p. ex. un dépôt sous vide ou une pulvérisation cathodique
H10K 59/122 - Structures ou couches définissant le pixel, p. ex. bords
A computer includes a processor and a memory, and the memory stores instructions executable by the processor to generate a set of points from a measurement scan obtained by a lidar sensor and to generate an expected termination distance of the set of points based on a neural implicit representation of the set of points. The instructions may additionally be to compute a loss function that includes a relatively low margin correlated with the variance or standard deviation of a training distribution centered at a learned point of the set of points based on the expected termination distance of the learned point, the learned point being learned by the neural implicit representation. The instructions may additionally be to generate a keyframe from the set of points and to generate a pose of the lidar sensor based on the keyframe.
TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOMEDICINE (Chine)
Inventeur(s)
Chen, Shuang
Wu, Haidong
Xu, Jie
Huang, Xiaoqiang
Chen, Yuqing E.
Abrégé
Provided herein are microRNA-derived RNAs and polypeptides and their uses as research, diagnostic, and therapeutic agents. In particular, provided herein are systems, compositions, and methods utilizing molecules derived from templated expression of RNA via a miRNA primer.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.
The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.
A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/7064 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées
C07D 239/70 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques
Methods of the disclosure include administration of a cholesterol analog imaging probe and correlation of change in the uptake of exogenous labeled cholesterol analogs as a marker for T cell activation.
C07J 1/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, non substitués en position 17bêta par un atome de carbone, p. ex. œstrane, androstane
An organic light emitting device comprises a first electrode, an organic emissive layer positioned over the first electrode, a charge transport layer positioned over the organic emissive layer, and a second electrode comprising a metal, positioned over the charge transport layer, wherein the charge transport layer and the second electrode are configured to form plasmon exciton polaritons between the second electrode and the charge transport layer, wherein the charge transport layer has large singlet extinction coefficients and oscillator strengths, and an absorption onset wavelength smaller than emission wavelength.
H10K 50/18 - Couches de blocage des porteurs de charge
H10K 50/852 - Dispositifs pour extraire la lumière des dispositifs comprenant une structure de cavité résonante, p. ex. une paire de réflecteurs de Bragg
The present disclosure relates to CD44-binding peptide reagents, methods for detecting cells such as hepatocellular carcinoma cells using the peptide reagents, and methods for targeting such cells using the peptide reagents.
Touchscreen devices, designed with an assumed range of user abilities and interaction patterns, often present challenges for individuals with diverse abilities to operate independently. Prior efforts to improve accessibility through tools or algorithms necessitated alterations to touchscreen hardware or software, making them inapplicable for the large number of existing legacy devices. This disclosure introduces a hardware interaction proxy that performs physical interactions on behalf of users while allowing them to continue utilizing accessible interfaces, such as screen readers and assistive touch on smartphones, for interface exploration and command input. The proxy maintains an interface model for accurate target localization and utilizes exchangeable actuators for physical actuation across a variety of device types, effectively reducing user workload and minimizing the risk of mistouch. Evaluations reveal that this approach lowers the mistouch rate and empowers visually and motor impaired users to interact with otherwise inaccessible physical touchscreens more effectively.
G06F 3/0488 - Techniques d’interaction fondées sur les interfaces utilisateur graphiques [GUI] utilisant des caractéristiques spécifiques fournies par le périphérique d’entrée, p. ex. des fonctions commandées par la rotation d’une souris à deux capteurs, ou par la nature du périphérique d’entrée, p. ex. des gestes en fonction de la pression exercée enregistrée par une tablette numérique utilisant un écran tactile ou une tablette numérique, p. ex. entrée de commandes par des tracés gestuels
G06F 3/041 - Numériseurs, p. ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction
G06F 3/042 - Numériseurs, p. ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction par des moyens opto-électroniques
G06F 3/044 - Numériseurs, p. ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction par des moyens capacitifs
A state-based framework is the basis for a methodology (30) for predicting faults in industrial equipment or processes during multi-stage degradation. The methodology (30) is based on an object-oriented scheme that allows system experts to identify signal trajectory classes (10) that may occur during degradation. The methodology (30) uses recent observations of a signal feature (x) to estimate the current health stage of a system and extrapolates signal trajectories forward in time to obtain probabilistic fault time estimates. The framework's ability to incorporate subject matter expertise reduces the need for extensive historical training data and includes an anomaly detection sub-process (44) to identify signal trends that deviate from expected behavior.
A device includes a substrate and a nanostructure supported by the substrate. The nanostructure includes a template segment supported by the substrate, the template segment including a nitride semiconductor material, and a ferroelectric segment supported by the template segment, the ferroelectric segment including a nitride alloy. The ferroelectric segment has a sub-micron lateral dimension.
University Hospitals Cleveland Medical Center (USA)
Inventeur(s)
Hamilton, Jesse
Lima Da Cruz, Gastao
Rajagopalan, Sanjay
Seiberlich, Nicole
Rashid, Imran
Abrégé
Methods and systems are provided for cine magnetic resonance fingerprinting (MRF). In one example, a method includes obtaining k-space data of an MRF scan of a subject, the k-space data acquired over a plurality of phases of at least one cardiac cycle of the subject, training an image reconstruction network (IRN) to output, for each phase, one or more subspace images of the subject using the k-space data, and training a parameter estimation network (PEN) to output, for each phase, a set of tissue parameter maps of the subject using the one or more subspace images output by the IRN for the corresponding phase. Upon training the IRN and the PEN, the method further includes obtaining (and displaying and/or saving in memory) a final set of tissue parameter maps of the subject for one or more or each of the plurality of phases.
G01R 33/561 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne par réduction du temps de balayage, c.-à-d. systèmes d'acquisition rapide, p. ex. utilisant des séquences d'impulsions écho-planar
G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
G01R 33/567 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne débloquées par des signaux physiologiques
Methods for electrocatalytic and thermocatalytic conversion of nitrate using PtxRuy/C catalysts are disclosed herein. The methods for electrocatalytic conversion of nitrate to ammonia can include contacting a nitrate containing source with an electrode comprising a PtxRuy/C catalyst while applying a potential sufficient to reduce nitrate to thereby convert nitrate present in the nitrate containing source to ammonia, wherein the PtxRuy/C catalyst comprises a carbon substrate having PtxRUy nanoparticles disposed thereon, and x is about 48 at % to about 90 at %, and y is 1−x.
Technologies for massively parallel data compression are disclosed. An example method includes receiving a data file, establishing a global offset at a first data of the data file, and substantially simultaneously causing a plurality of threads of a graphics processing unit (GPU) to compare respective data sequences with a first data sequence that includes the first data. Each thread of the plurality of threads may compare a different respective data sequence, and each respective data sequence may be offset from every other respective data sequence and the first data sequence. The example method may further include determining a optimal data sequence corresponding to the first data sequence from the respective data sequences, storing the optimal data sequence in a reference table, updating the global offset based on the optimal data sequence, and iteratively performing these steps until the global offset is a beginning or an end of the data file.
A bladder drainage and irrigation pump system includes a pump subsystem, a housing subsystem, an electrical subsystem, and a user interface subsystem. The pump, which may be a peristaltic pump, actuates fluid through a length of flexible tubing in a direction away from a catheter in fluid communication with a catheter-end port, toward a drainage outlet port. A controller of the system terminates a drainage cycle once a pressure sensor detects a change in pressure indicative of the bladder being substantially empty. An irrigation cycle is then initiated during which the direction of the pump is reversed and irrigation fluid is delivered via the catheter to the bladder. The pump then drains the used irrigant out of the bladder. An intuitive user interface is used to separately initiate drainage and irrigation cycles.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
Technologies for massively parallel data compression are disclosed. An example method includes receiving a data file, establishing a global offset at a first data of the data file, and substantially simultaneously causing a plurality of threads of a graphics processing unit (GPU) to compare respective data sequences with a first data sequence that includes the first data. Each thread of the plurality of threads may compare a different respective data sequence, and each respective data sequence may be offset from every other respective data sequence and the first data sequence. The example method may further include determining a optimal data sequence corresponding to the first data sequence from the respective data sequences, storing the optimal data sequence in a reference table, updating the global offset based on the optimal data sequence, and iteratively performing these steps until the global offset is a beginning or an end of the data file.
Provided herein are systems, compositions, and methods for delivering cytokines and other desired molecules to the brain using a three-component system: 1) a targeting component that binds to a brain-specific molecule (e.g., brain-specific protein); 2) a targeting component that facilitates shuttling of the system across the blood-brain barrier; and 3) an anti-inflammatory and/or immunosuppressive molecule (e.g., cytokine).
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
Compositions suitable for reversibly storing heat in thermal energy systems (TES) include a salt hydrate represented by the formula: MXq·nH2O. M is a cation selected from Groups 1 to 14 of the IUPAC Periodic Table, X is a halide of Group 17, q ranges from 1 to 4, and n ranges from 1 to 12. The cation (M) may have an electronegativity of ≤ about 1.8 and a molar mass ≤ about 28 g/mol. The anion (X) may have an electronegativity of ≥about 2.9 to ≤ about 3.2. A distance between a cation (M) and coordinating water molecules (H2O) is ≤ about 2.1 Å. Thermal energy systems (TES) incorporating such compositions are also provided that are configured to reversibly store heat in the thermal energy system (TES) via an endothermic dehydration reaction and to release heat in in the thermal energy system (TES) via an exothermic hydration reaction.
An optical phased array device, and method of fabricating an optical phased array device, where the optical phased array device has a plurality of self-aligned waveguides having an on-chip edge coupler at which a single mode optical fiber is coupled to each of the plurality of self-aligned waveguides; and/or has a fiber coupling interface and a plurality of waveguide layers sharing a common edge at the fiber coupling interface, wherein the fiber coupling interface is configured to couple a single mode optical fiber to each of the plurality of waveguide layers at the common edge. The method includes fabricating an optical phased array according to a layer thickness for one or more waveguide layers, wherein the layer thickness is determined based on mode matching data derived from a mode profile at an input coupling interface.
G02B 6/12 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
G02B 6/13 - Circuits optiques intégrés caractérisés par le procédé de fabrication
G02B 6/293 - Moyens de couplage optique ayant des bus de données, c.-à-d. plusieurs guides d'ondes interconnectés et assurant un système bidirectionnel par nature en mélangeant et divisant les signaux avec des moyens de sélection de la longueur d'onde
51.
SELF-ALIGNED THREE-DIMENSIONAL OPTICAL PHASED ARRAY AND FABRICATION THEREOF
An optical phased array, device incorporating the same, and method for fabricating the same. The method, describable as a method for fabricating a three-dimensional (3D) optical phased array (OPA), includes: simultaneously etching multiple waveguide-cladding layers to form a plurality of waveguide paths, each of which terminates at a common edge; and/or generating a waveguide-cladding stack having a plurality of waveguide layers and a plurality of cladding layers, and simultaneously etching multiple layers of a waveguide-cladding stack to form a plurality of waveguide paths, each of which terminates at a common edge. The optical phased array has a plurality of self-aligned waveguide layers.
G02B 6/12 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
G02B 6/293 - Moyens de couplage optique ayant des bus de données, c.-à-d. plusieurs guides d'ondes interconnectés et assurant un système bidirectionnel par nature en mélangeant et divisant les signaux avec des moyens de sélection de la longueur d'onde
52.
VENTILATION ASSESSMENT SYSTEM, FACE MASK, AND METHOD
A method of assessing ventilation and a system for assessing ventilation integrate sensor-based force outputs with graphical, real-time feedback for positive pressure ventilation (PPV), particularly for infants. In one implementation, the method includes receiving a measurement of an applied force between a face mask and a face of a patient from a first sensor located at least partially between the face mask and the face of the patient, receiving a measurement of an overall force applied to the patient from a second sensor, and contextualizing the measured applied force and the measured overall force to provide a graphical user interface.
The present disclosure relates to compositions, systems, and methods for characterizing cancer and determining a treatment course of action. In particular, the present disclosure relates to compositions, systems, and methods for utilizing gene expression and methylation profiles to stratify and treat adrenocortical carcinoma.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A device includes a substrate and a heterostructure supported by the substrate, the heterostructure including a semiconductor stack supported by the substrate, the semiconductor stack defining a junction, and a nanostructure including a layered material, the nanostructure being disposed between the semiconductor stack and the substrate and configured such that radiative recombination of charge carriers reaching the nanostructure via the junction and the substrate is achieved.
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
H01L 25/16 - Ensembles consistant en une pluralité de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide les dispositifs étant de types couverts par plusieurs des sous-classes , , , , ou , p. ex. circuit hybrides
C30B 25/18 - Croissance d'une couche épitaxiale caractérisée par le substrat
55.
METHODS OF TREATING DIGESTIVE DISEASES AND COMPOSITIONS THEREOF
e.g.e.g., digestive diseases) by administering an antibody or an antigen portion thereof that binds to sLeA and a TNFα inhibitor, as well as pharmaceutical compositions related thereto.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
An optical phased array device, and method of fabricating an optical phased array device, where the optical phased array device has a plurality of self-aligned waveguides having an on-chip edge coupler at which a single mode optical fiber is coupled to each of the plurality of self-aligned waveguides; and/or has a fiber coupling interface and a plurality of waveguide layers sharing a common edge at the fiber coupling interface, wherein the fiber coupling interface is configured to couple a single mode optical fiber to each of the plurality of waveguide layers at the common edge. The method includes fabricating an optical phased array according to a layer thickness for one or more waveguide layers, wherein the layer thickness is determined based on mode matching data derived from a mode profile at an input coupling interface.
G02B 6/12 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
G02B 6/13 - Circuits optiques intégrés caractérisés par le procédé de fabrication
57.
SELF-ALIGNED THREE-DIMENSIONAL OPTICAL PHASED ARRAY AND FABRICATION THEREOF
An optical phased array, device incorporating the same, and method for fabricating the same. The method, describable as a method for fabricating a three-dimensional (3D) optical phased array (OPA), includes: simultaneously etching multiple waveguide-cladding layers to form a plurality of waveguide paths, each of which terminates at a common edge; and/or generating a waveguide-cladding stack having a plurality of waveguide layers and a plurality of cladding layers, and simultaneously etching multiple layers of a waveguide-cladding stack to form a plurality of waveguide paths, each of which terminates at a common edge. The optical phased array has a plurality of self-aligned waveguide layers.
G02B 6/136 - Circuits optiques intégrés caractérisés par le procédé de fabrication par gravure
G02B 6/12 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
G01S 7/481 - Caractéristiques de structure, p. ex. agencements d'éléments optiques
A gasification reactor for conversion of a feedstock to syngas and biochar. The gasification reactor includes a biomass input configured to receive feedstock, a gasifying medium inlet adjacent to the biomass input and configured to receive a gasifying medium, and a reactor vessel configured to gasify the feedstock with the gasifying medium to generate syngas and biochar. The reactor vessel is disposed downstream of the gasifying medium inlet. The reactor vessel may comprise cement along an inner surface of the reactor vessel. The reactor vessel may further comprise a blower coupled to the gasifying medium inlet to drive the gasifying medium into the reactor vessel. The reactor vessel may further comprise a biomass movement instrument to regulate the flow of the feedstock.
C01B 3/32 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p. ex. de l'eau, du gaz carbonique, de l'air
C01B 3/02 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène
C01B 3/34 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés organiques gazeux ou liquides avec des agents gazéifiants, p. ex. de l'eau, du gaz carbonique, de l'air par réaction d'hydrocarbures avec des agents gazéifiants
C10K 3/02 - Modification de la composition chimique des gaz combustibles contenant l'oxyde de carbone en vue de produire un carburant amélioré, p. ex. un carburant de pouvoir calorifique différent qui peut ne pas contenir d'oxyde de carbone par traitement catalytique
59.
VACCINE COMPOSITIONS, COMPONENTS, AND METHODS OF USE
The present disclosure provides vaccine components and compositions, and methods of use thereof. More specifically, the disclosure provides compositions comprising one or more T cell epitopes(e.g., one or more tumor-associated T cell epitopes and/or one or more T cell epitopes derived from a microorganism), or a nucleic acid encoding thereof, and one or more B cell epitopes, or a nucleic acid encoding thereof. The disclosure also provides RNA molecules (e.g., mRNA molecules) encoding B cell epitopes to mediate B cell antigen presentation, magnetic nanoparticles comprising antigen clusters having B cell and/or T cell epitopes, and compositions and vaccines (e.g., cancer vaccines) thereof.
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
A61K 47/52 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé inorganique, p. ex. un ion inorganique complexé avec l’ingrédient actif
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
A gasification reactor for conversion of a feedstock to syngas and biochar. The gasification reactor includes a biomass input configured to receive feedstock, a gasifying medium inlet adjacent to the biomass input and configured to receive a gasifying medium, and a reactor vessel configured to gasify the feedstock with the gasifying medium to generate syngas and biochar. The reactor vessel is disposed downstream of the gasifying medium inlet. The reactor vessel may comprise cement along an inner surface of the reactor vessel. The reactor vessel may further comprise a blower coupled to the gasifying medium inlet to drive the gasifying medium into the reactor vessel. The reactor vessel may further comprise a biomass movement instrument to regulate the flow of the feedstock.
Systems for inferring spatially-varying regulatory networks, such as gene regulatory networks, are provided. Optimization processes are performed and include regularization minimization processes that rely on one or both of a smoothly-changing minimization process and a sparsely-changing minimization process, for example to learn sparsely- or smoothly-changing Gaussian Markov random fields (GMRF). The systems are further able to convert spatially-varying data, such as spatial transcriptomic data, into spatio-temporal regulatory networks.
G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
A state-based framework is the basis for a methodology for predicting faults in industrial equipment or processes during multi-stage degradation. The methodology is based on an object-oriented scheme that allows system experts to identify signal trajectory classes that may occur during degradation. The methodology uses recent observations of a signal feature to estimate the current health stage of a system and extrapolates signal trajectories forward in time to obtain probabilistic fault time estimates. The framework's ability to incorporate subject matter expertise reduces the need for extensive historical training data and includes an anomaly detection sub-process to identify signal trends that deviate from expected behavior.
Provided herein are agents that increase a subject's sensitivity to anti-obesity and/or anorectic agents, allowing, for example, for decreased dosage or enhanced efficacy of treatment of obesity or related disorders. In particular, inhibitors of melanocortin 3 receptor (MC3R) expression or activity and/or activators of MC4R expression or activity are provided as anorexia-sensitizing agents for co-administration with anti-obesity and/or anorectic agents.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
The present disclosure provides porous three dimensional polymeric devices useful for purifying and/or isolating a target cell-derived component (e.g., extracellular vesicles), and methods of making and systems or kits comprising thereof. Wherein the three-dimensional device is a cube that comprises a polymer, and wherein the polymer comprises polydimethylsiloxane (PDMS).
The present disclosure provides acoustically-responsive scaffold (ARS) precursor formulations comprising fibrinogen, alginate, hyaluronic acid, or a combination thereof, acoustically-responsive scaffolds comprising spatially patterned phase-shift emulsions (PSEs), and methods of using thereof (e.g., as implants, for tissue repair or regeneration and/or delivery of therapeutic agents).
A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux
B29K 105/00 - Présentation, forme ou état de la matière moulée
B29K 105/24 - Présentation, forme ou état de la matière moulée réticulée ou vulcanisée
An optical arrangement for use in an endoscope is provided. The endoscope includes a single mode fiber for providing illumination, a collimator connected to the single mode fiber for producing a low numerical aperture beam, a scanner for reflecting the beam produced by the collimator, and a multimode fiber for collecting return light. Structural components for creating a compact arrangement may include an outer tube, a flexible tube, and an end tube. An optical system using the optical arrangement may further include an optical train having a plurality of dichroic mirrors, and a plurality of photomultiplier tube detectors.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p. ex. des fibres optiques
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A magnetometer system having a magneto-inductive sensor configured to provide satellite attitude determination, magnetic noise identification, and magnetic field information; electronics operably coupled to the sensor configured to protect against electrostatic discharge and measure temperature of the sensor for thermal calibration; and an aluminum chassis supporting and protecting the sensor.
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Soto-Gutierrez, Alejandro
Takeishi, Kazuki
Morita, Kazutoyo
Haep, Nils
Florentino, Rodrigo Machado
Achreja, Abhinav
Nagrath, Deepak
Animasahun, Olamide
Yoshizumi, Tomoharu
Abrégé
Methods are disclosed for inhibiting a liver disease in a subject. These methods include administering to the subject an effective amount of a phosphodiesterase (PDE) III inhibitor or 10,12-tricosadiynoic acid (TDYA), or a pharmaceutically acceptable salt thereof, thereby treating or preventing the liver disease in the subject. Also disclosed are compositions including an effective amount of a phosphodiesterase (PDE) III inhibitor or 10,12-tricosadiynoic acid (TDYA), or a pharmaceutically acceptable salt thereof, for use in inhibiting liver disease in a subject.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
70.
ARTIFICIAL TESTIS CELLS AND METHOD FOR THEIR PRODUCTION
in vitroin vitro methods for production of testis cells (e.g., Sertoli and/or Leydig cells) and related organoids. The testis cells and testis like organoids may be used for therapeutic purposes including facilitation of the production of spermatogonia from pro-spermatogonia stem cells.
An ultrasound bone densitometer employs transmitted ultrasound and laser stimulated ultrasound to provide a more complete measure of bone health. Sources of error including secondary laser stimulation, signal dependency on direction of laser light travel, registration, and signal chain noise are addressed in the construction of the densitometer.
A method is disclosed for suppressing propagation of a metal in a solid state electrolyte during cycling of an electrochemical device including the solid state electrolyte and an electrode comprising the metal. One method comprises forming the solid state electrolyte such that the solid state electrolyte has a structure comprising a plurality of grains of a metal-ion conductive material and a grain boundary phase located at some or all of grain boundaries between the grains, wherein the grain boundary phase suppresses propagation of the metal in the solid state electrolyte during cycling. Another method comprises forming the solid state electrolyte such that the solid state electrolyte is a single crystal.
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
74.
POWERED PROSTHESIS WITH HYBRID CONTROLLER FOR STAIR LOCOMOTION
A powered prosthesis includes a phase-based hybrid kinematic and impedance controller (HKIC) that facilitates semi -volitional, biomimetic stair ascent and descent at a variety of step heights. A unified phase variable for both stair ascent and descent uses lower-limb geometry to adjust to different users and step heights. A modified cost function and constraint are used to create a continuously varying impedance parameter model for stair ascent and descent over a continuum of step heights. Experiments with above-knee amputee participants confirms that the controller produces biomimetic ascent and descent joint kinematics, kinetics, and work across multiple step height configurations. The controller results in a powered prosthesis with improved kinematic performance in comparison with a passive microprocessor-controlled device during stair locomotion.
A method of operating a spa includes the following steps. Sensing a plurality of physical and chemical spa water qualities, including oxidation reduction potential (ORP), acidity (pH), and conductivity, using at least one sensor in fluid communication with spa water and in electrical communication with a spa controller. Adjusting spa chemistry in response to one or more of the plurality of fluid conditions, wherein the spa controller receives data from the at least one sensor and, based on the data received, controls one or more chemical treatment components to input chemicals into the spa water. A related apparatus is also disclosed.
An all-epitaxial, electrically injected surface-emitting green laser operates in a range of about 520-560 nanometers (nm). At 523 nm, for example, the device exhibits a threshold current density of approximately 0.4 kilo-amperes per square centimeter (kA/cm2), which is over one order of magnitude lower than that of previously reported blue laser diodes.
H01S 5/34 - Structure ou forme de la région activeMatériaux pour la région active comprenant des structures à puits quantiques ou à superréseaux, p. ex. lasers à puits quantique unique [SQW], lasers à plusieurs puits quantiques [MQW] ou lasers à hétérostructure de confinement séparée ayant un indice progressif [GRINSCH]
H01S 5/11 - Structure ou forme du résonateur optique comprenant une structure de bande photonique interdite
H01S 5/183 - Lasers à émission de surface [lasers SE], p. ex. comportant à la fois des cavités horizontales et verticales comportant uniquement des cavités verticales, p. ex. lasers à émission de surface à cavité verticale [VCSEL]
H01S 5/30 - Structure ou forme de la région activeMatériaux pour la région active
H01S 5/32 - Structure ou forme de la région activeMatériaux pour la région active comprenant des jonctions PN, p. ex. hétérostructures ou doubles hétérostructures
H01S 5/323 - Structure ou forme de la région activeMatériaux pour la région active comprenant des jonctions PN, p. ex. hétérostructures ou doubles hétérostructures dans des composés AIIIBV, p. ex. laser AlGaAs
H01S 5/343 - Structure ou forme de la région activeMatériaux pour la région active comprenant des structures à puits quantiques ou à superréseaux, p. ex. lasers à puits quantique unique [SQW], lasers à plusieurs puits quantiques [MQW] ou lasers à hétérostructure de confinement séparée ayant un indice progressif [GRINSCH] dans des composés AIIIBV, p. ex. laser AlGaAs
77.
VASCULAR RESISTANCE AND BLOOD PRESSURE MEASUREMENT USING COMBINED PIEZOELECTRIC AND PHOTOPLETHYSMOGRAM MEASUREMENT
Systems and methods are provided for non-invasively measuring one or more hemodynamic variables using a peripheral arterial region wearable device having a strain sensor and a photoplethysmogram sensor. Different line fit profiles are determined from device collected signals indicative of the strain response versus externally applied cuff pressure and the blood volume and/or the blood circulation changes versus externally applied cuff pressure. From these line fit profiles, external cuff pressure affected line fit features are determined, from which hemodynamic variables for the peripheral arterial region such as blood pressure and/or a systemic vascular resistance are then determined.
A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
A61B 5/022 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par application d'une pression pour fermer les vaisseaux sanguins, p. ex. contre la peauOphtalmodynamomètres
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
78.
TECHNOLOGIES FOR UTILIZING RETINAL OXIMETRY TO MEASURE BLOOD OXYGEN LEVELS
Technologies for utilizing retinal oximetry to measure blood oxygen levels are disclosed. An example method includes capturing, by one or more imagers of a handheld imaging device, at least two images of a retinal vasculature. The example method further includes determining (i) a first optical density of the retinal vasculature represented in a first image of the at least two images and (ii) a second optical density of the retinal vasculature represented in a second image of the at least two images; and determining an optical density ratio of the retinal vasculature based on the first optical density and the second optical density. The example method further includes determining a traumatic brain injury (TBI) likelihood value corresponding to the optical density ratio; and outputting the TBI likelihood value for display to a user.
Systems and methods for aligning gas chromatography peaks are disclosed. An example method includes receiving chromatographic data of a user that includes data representing at least one volatile organic compound (VOC), and analyzing the chromatographic data using a trained peak alignment model to output a set of peak match probabilities. The trained peak alignment model may be trained using a plurality of chromatographic data to output a plurality of peak match probabilities. The example method may further include generating a set of identified VOCs between the chromatographic data and a set of reference VOCs by applying a post-processing algorithm to the set of peak match probabilities; and causing the set of identified VOCs to be displayed to the user.
An atomic layer deposition system comprises: a depositor head having an active surface configured to discharge a first precursor gas, a second precursor gas, and an inert gas that separates the first precursor gas and the second precursor gas; a substrate spaced apart from the active surface of the depositor head; an XY motion device operably coupled to the substrate or the depositor head; and a controller configured to execute a program stored in the controller to move the XY motion device such that the substrate or the depositor head moves in a path, wherein a position of the substrate relative to the depositor head varies in both an X direction and a Y direction when the substrate or the depositor head follows the path. Also disclosed are a method for atomic layer deposition, and a method for reducing non-uniformity of a film produced by atomic layer deposition.
C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
C23C 16/458 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour supporter les substrats dans la chambre de réaction
C23C 16/52 - Commande ou régulation du processus de dépôt
81.
PHYLOGENETIC PLACEMENT USING TAXONOMY-INDEPENDENT FEATURE GENERATION
Methods and systems for generating improved taxonomy-independent, generalizable features of alleles. The systems and methods may include (1) receiving a plurality of amplicon sequence variants corresponding to one or more microorganism communities; (2) generating a de novo phylogenetic tree representing a plurality of full-length and non-clustered alleles and the plurality of amplicon sequence variants; (3) generating a set of one or more phylogenetically-binned amplicon sequence variants (phylotypes) by a divide-and-conquer strategy; and/or (4) storing the set of phylotypes in one or more computer memories.
G16B 50/30 - Entreposage de donnéesArchitectures informatiques
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
82.
IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF
The present disclosure provides compounds represented by Formula I:
The present disclosure provides compounds represented by Formula I:
The present disclosure provides compounds represented by Formula I:
wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.
C07D 491/22 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus dans les groupes , , ou dans lesquels le système condensé contient au moins quatre hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07D 471/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes du système condensé, au moins un cycle étant un cycle à six chaînons avec un atome d'azote, non prévus dans les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 495/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 498/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 513/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient au moins quatre hétérocycles
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
83.
MACHINE LEARNING AND DATA CLASSIFICATION FOR OPERATING A DEVICE SUCH AS A VEHICLE
A computer that includes a processor and a memory, the memory including instructions executable by the processor to input an image to a first neural network to generate a first detected object and input the image to a second neural network to generate a reconstructed image which is input to a third neural network to generate a second detected object. The image can be divided into portions and the portions input to respective fourth neural networks to generate portions of a third detected object. The first detected object, the second detected object, the portions of the third detected object, and context data can be input to a partially observable Markov decision process to generate a high confidence detected object.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 20/58 - Reconnaissance d’objets en mouvement ou d’obstacles, p. ex. véhicules ou piétonsReconnaissance des objets de la circulation, p. ex. signalisation routière, feux de signalisation ou routes
G06V 20/70 - Étiquetage du contenu de scène, p. ex. en tirant des représentations syntaxiques ou sémantiques
84.
ANATOMICAL AND FUNCTIONAL ASSESSMENT OF CORONARY ARTERY DISEASE USING MACHINE LEARNING
Anatomical and functional assessment of coronary artery disease (CAD) using machine learning and computational modeling techniques deploying methodologies for non-invasive Fractional Flow Reserve (FFR) quantification based on angiographically derived anatomy and hemodynamics data, relying on machine learning algorithms for image segmentation and flow assessment, and relying on accurate physics-based computational fluid dynamics (CFD) simulation for computation of the FFR.
An atomic layer deposition system comprises: a depositor head having an active surface configured to discharge a first precursor gas, a second precursor gas, and an inert gas that separates the first precursor gas and the second precursor gas; a substrate spaced apart from the active surface of the depositor head; an XY motion device operably coupled to the substrate or the depositor head; and a controller configured to execute a program stored in the controller to move the XY motion device such that the substrate or the depositor head moves in a path, wherein a position of the substrate relative to the depositor head varies in both an X direction and a Y direction when the substrate or the depositor head follows the path. Also disclosed are a method for atomic layer deposition, and a method for reducing non-uniformity of a film produced by atomic layer deposition.
C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
86.
KITS AND METHODS USEFUL FOR PROGNOSING, DIAGNOSING, AND TREATING PROSTATE CANCER
Provided herein are kits and methods useful for cancer diagnosis, prognosis, research and therapy. In particular, provided herein are methods of diagnosing, prognosing, and/or treating prostate cancer based on expression levels of cancer markers.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
87.
REGULATING T CELL IMMUNE RESPONSE THROUGH IGF-I RECEPTOR (IGF-1R)
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Provided herein is technology relating to analyte detection and particularly, but not exclusively, to compositions, methods, systems, and kits for high-specificity detection of analytes using molecular probes that integrate cumulative repeated binding of probes to the same analyte molecule.
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (USA)
ACADEMISCH ZIEKENHUIS GRONINGEN (Pays‑Bas)
RIJKSUNIVERSITEIT GRONINGEN (Pays‑Bas)
Inventeur(s)
Kretzler, Matthias
Bjornstad, Petter
Ju, Wenjun
Nair, Viji
Lambers Heerspink, Hiddo
Abrégé
Provided herein are compositions and methods for treating and preventing kidney disease. In particular, provided herein are methods of treating and preventing kidney disease with SGLT2 inhibitors in a subject with low levels of urinary EGF.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
90.
IMPROVING PHYLOGENETIC PLACEMENT USING TAXONOMY-INDEPENDENT FEATURE GENERATION
de novode novo phylogenetic tree representing a plurality of full-length and non-clustered alleles and the plurality of amplicon sequence variants; (3) generating a set of one or more phylogenetically-binned amplicon sequence variants (phylotypes) by a divide-and-conquer strategy; and/or (4) storing the set of phylotypes in one or more computer memories.
G16B 10/00 - TIC spécialement adaptées à la bio-informatique évolutive, p. ex. construction ou analyse d’arbre phylogénétique
G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (Chine)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
LIVZON PHARMACEUTICAL GROUP INC. (Chine)
Inventeur(s)
Ding, Ke
Liu, Lianchao
Wang, Zhen
Chinnaiyan, Arul M.
Paroli, Abhijit
Abrégé
The present invention provides an NSD protein degradation agent and a use thereof. Specifically, the present invention provides a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer or prodrug molecule thereof. The compound can degrade proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3/PSA, AR, NKX3.1, and GSPT1 via target ubiquitination, and therefore can be used to treat indications related to abnormal expression of proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3/PSA, AR, NKX3.1, and GSPT1.
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
92.
Frequency-Dependent Non-Thermal Plasma Inactivation Of Airborne Pathogens
The degree of airborne virus inactivation, along with non-thermal plasma power, are dependent on the AC driving frequency used to energize the non-thermal plasma. As such, for AC-power non-thermal plasma air sterilization, there exists one or more frequencies at which dramatically enhanced pathogen inactivation can be achieved. The identification of the frequencies associated with peak pathogen inactivation, peak non-thermal plasma power (per volumetric flow rate), and peak ozone offers opportunities for optimization to achieve highest pathogen inactivation while consuming less power and producing less harmful ozone. Advanced non-thermal plasma-based air sterilization technologies could be based on systems designed with such optimization strategies.
Provided herein are compositions and methods for generation of cysteine in microbial systems. Further provided herein are compositions and methods for reducing and eliminating biofilms.
Event-based cameras are inspired by the sparse and asynchronous spike representation of the biological visual system. However, processing the event data requires either using expensive feature descriptors to transform spikes into frames, or using spiking neural networks that are expensive to train. This disclosure proposes a neural network architecture, Reservoir Nodes-enabled neuromorphic vision sensing Network (RN-Net), based on simple convolution layers integrated with dynamic temporal encoding reservoirs for local and global spatiotemporal feature detection with low hardware and training costs. The RN-Net allows efficient processing of asynchronous temporal features, and achieves the highest accuracy of 99.2% for DVS128 Gesture reported to date, and one of the highest accuracy of 67.5% for DVS Lip dataset at a much smaller network size. By leveraging the internal device and circuit dynamics, asynchronous temporal feature encoding can be implemented at very low hardware cost without preprocessing and dedicated memory and arithmetic units.
H04N 25/47 - Capteurs d'images avec sortie d'adresse de pixelCapteurs d'images commandés par événementSélection des pixels à lire en fonction des données d'image
95.
SLC2A1/GLUT1 AS A BIOMARKER FOR HIGH-RISK EPITHELIAL DYSPLASIA
Provided herein are methods of stratifying oral lesions based upon risk of progressing to malignancy, and methods of treating a subject involving selectively removing oral lesions identified to be high risk. In some aspects, the methods provided herein comprise assessing risk based upon expression of SLC2A1 on the lesion.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
96.
Accelerator Architecture For A Transformer Machine Learning Model
An accelerator architecture is presented for a Transformer machine learning model. The accelerator is comprised of: one or more memory devices, each memory device has a random access memory and is configured for processing in memory, where a key matrix, a value matrix, a query weight matrix, a key weight matrix, and a value weight matrix for an attention mechanism of the Transformer machine learning model are stored in the one or more memory devices; and a control device interfaced with each of the one or more memory devices, the control device is used to coordinate the vector matrix multiplication operations performed on the memory devices, perform other arithmetic and logic operations used in attention blocks that are not suited for the memory devices, and coordinate the updates of the key and value matrices in the one or more memory devices.
The degree of airborne virus inactivation, along with non-thermal plasma power, are dependent on the AC driving frequency used to energize the non-thermal plasma. As such, for AC-power non-thermal plasma air sterilization, there exists one or more frequencies at which dramatically enhanced pathogen inactivation can be achieved. The identification of the frequencies associated with peak pathogen inactivation, peak non-thermal plasma power (per volumetric flow rate), and peak ozone offers opportunities for optimization to achieve highest pathogen inactivation while consuming less power and producing less harmful ozone. Advanced non-thermal plasma-based air sterilization technologies could be based on systems designed with such optimization strategies.
To train a machine learning algorithm to identify DNA sequences, an electrochemical sensor detects a set of electrical signals from each of a plurality of standards each representing a known sequence. A computing device obtains the sets of electrical signals and trains a machine learning model to identify a sequence using, for each of the standards, (i) characteristics of the set of electrical signals, and (ii) the known sequence of the standard. The electrochemical sensor detects a set of electrical signals from a DNA sequence from a patient having an unknown sequence. The computing device obtains the set of electrical signals from the patient DNA sequence and applies characteristics of the set of electrical signals from the patient DNA sequence to the trained machine learning model to identify a sequence for the patient DNA sequence.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventeur(s)
Dayton, Paul Alexander
Kim, Jinwook
Jiang, Xiaoning
Zhang, Bohua
Wu, Huaiyu
Xu, Zhen
Abrégé
A method for disrupting a blood clot with ultrasound and at least one cavitation enhancing agent includes administering at least one cavitation enhancing agent into a blood vessel of a subject. The method further includes monitoring the at least one cavitation enhancing agent to determine when at least a portion of the at least one cavitation enhancing agent has reached a blood clot. The method further includes controlling application of ultrasound energy to the at least one cavitation enhancing agent within the blood vessel of the subject such that, during a first time period, cavitation-enhancing ultrasound energy is not applied to the at least one cavitation enhancing agent within the blood vessel and, during a second time period after the first time period, cavitation enhancing ultrasound energy is applied to the at least one cavitation enhancing agent within the blood vessel.
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
100.
Wavelet-Adaptive Interference Cancellation For Underdetermined Platforms
An interference removal technique, called Wavelet-Adaptive Interference Cancellation for Underdetermined Platforms (WAIC-UP), is provided to effectively eliminate stray magnetic field signals using multiple magnetometers, without requiring prior knowledge of the spectral content, location, or magnitude of the interference signals. WAIC-UP capitalizes on the distinct spectral properties of various interference signals and employs an analytical method to separate them from ambient magnetic field in the wavelet domain.
